Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGENUS INCAGEN · Entity 5774 | Director · See Remarks | August 10, 2026 | August 13, 2026 |
| MiNK Therapeutics, Inc.INKT · Entity 52 | Director | May 05, 2023 | May 26, 2023 |
| Protagenic Therapeutics, Inc.\newPTIX · Entity 8496 | Director · EXEC. CHAIR & PRINCIPAL OFF | August 21, 2026 | August 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGENUS INC
Report date August 10, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $7.78 · Expires 2036-08-10 | Direct | 1,971,500 |
Reported balance
After 2026-08-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-10 · Grant · Acquired 1,971,500 · Balance 1,971,500 F1: Option awarded in accordance with the Agenus Inc. Amended and Restated 2019 Equity Incentive Plan. The options are divided into five equal tranches, each of which vests only if the Company's stock price achieves and sustains, for 30 consecutive calendar days during the five-year performance period, a level equal to 3x, 4x, 5x, 6x, and 8x, respectively, of the measurement price of $7.78 per share, subject in each case to a minimum three-year service requirement. |
Filing footnotes · ownership attribution and instrument terms
F1: Option awarded in accordance with the Agenus Inc. Amended and Restated 2019 Equity Incentive Plan. The options are divided into five equal tranches, each of which vests only if the Company's stock price achieves and sustains, for 30 consecutive calendar days during the five-year performance period, a level equal to 3x, 4x, 5x, 6x, and 8x, respectively, of the measurement price of $7.78 per share, subject in each case to a minimum three-year service requirement.
MiNK Therapeutics, Inc.
Report date May 05, 2023 · Filed May 26, 2023 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,966,400 |
Reported balance
Holding disclosure · report date 2023-05-05 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 1,966,400 F1: On May 5, 2023, Garo Armen, the CEO and Chairman of Agenus, disclosed a transaction involving 100,000 MiNK Therapeutics shares. He agreed to sell these shares to Agenus at his original purchase price, which was lower than the market price at the time of the proposed sale. This action was taken to prevent any perception of Dr. Armen benefitting from low-cost purchases while Agenus was buying at higher prices in separate transactions. However, due to the shares being in Dr. Armen's IRA account, their transfer was prohibited, leading the broker to reverse the sale and decline Agenus' payment. Consequently, the MiNK Therapeutics shares were returned to Dr. Armen, and the sale price was given back to Agenus. This amendment accounts for the changes in Dr. Armen's share ownership following the reversal of this transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 5, 2023, Garo Armen, the CEO and Chairman of Agenus, disclosed a transaction involving 100,000 MiNK Therapeutics shares. He agreed to sell these shares to Agenus at his original purchase price, which was lower than the market price at the time of the proposed sale. This action was taken to prevent any perception of Dr. Armen benefitting from low-cost purchases while Agenus was buying at higher prices in separate transactions. However, due to the shares being in Dr. Armen's IRA account, their transfer was prohibited, leading the broker to reverse the sale and decline Agenus' payment. Consequently, the MiNK Therapeutics shares were returned to Dr. Armen, and the sale price was given back to Agenus. This amendment accounts for the changes in Dr. Armen's share ownership following the reversal of this transaction.
Protagenic Therapeutics, Inc.\new
Report date August 21, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 73,533 |
Reported balance
After 2026-08-21 transaction · row 1
1 source rowRow 1 · 2026-08-21 · Purchase · Acquired 20,000 · Balance 73,533 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 19, 2019 Filed Jan 10, 2020 19:00 UTC Amendment | AGENUS INC AGEN · Entity 5774 | OtherCommon Stock | 195,358 | $3.77 | $736,499.66 |
DisclosureSEC source: 0000899243-20-000941 · doc4a.xml · nonDerivative · entry 3 ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,101,075 F4 · security: This line amends and restates Table 1, Line 5 of the Statement of Changes in Beneficial Ownership as originally filed to correct the amount of securities beneficially owned following the reported transaction. F1 · kind: This line represents a new transaction that is being added to the Statement of Changes in Beneficial Ownership as originally filed. Read SEC document |
| December 17, 2019 Filed Dec 23, 2019 22:33 UTC | AGENUS INC AGEN · Entity 5774 | OtherCommon Stock | 66,000 | $3.88 | $256,080.00 |
DisclosureSEC source: 0001745285-19-000018 · primary_doc.xml · nonDerivative · entry 4 ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,230,433 F1 · kind: Represents shares donated to a charitable organization. Read SEC document |
| December 17, 2019 Filed Jan 10, 2020 19:00 UTC Amendment | AGENUS INC AGEN · Entity 5774 | OtherCommon Stock | 66,000 | $3.88 | $256,080.00 |
DisclosureSEC source: 0000899243-20-000941 · doc4a.xml · nonDerivative · entry 2 ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,296,433 F3 · security: This line amends and restates Table 1, Line 4 of the Statement of Changes in Beneficial Ownership as originally filed to correct the amount of securities beneficially owned following the reported transaction. F1 · kind: This line represents a new transaction that is being added to the Statement of Changes in Beneficial Ownership as originally filed. Read SEC document |
| December 17, 2019 Filed Jan 10, 2020 19:00 UTC Amendment | AGENUS INC AGEN · Entity 5774 | OtherCommon Stock | 66,000 | $3.88 | $256,080.00 |
DisclosureSEC source: 0000899243-20-000941 · doc4a.xml · nonDerivative · entry 1 ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,362,433 F1 · security: This line represents a new transaction that is being added to the Statement of Changes in Beneficial Ownership as originally filed. F2 · kind: Represents a distribution from the Garo Armen 2018 2 Year AG GRAT. Read SEC document |
| November 20, 2019 Filed Feb 24, 2020 19:12 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | PurchaseConvertible Note · Derivative | Not disclosed | $200,000.00 Strike: $1.25 | $200,000.00 |
DisclosureSEC source: 0001493152-20-002879 · ownership.xml · derivative · entry 1 ARMEN GARO H · CIK 0000935679 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common stock, par value $0.0001 per share · 160,000 shares Expires 2023-11-06 F1 · security: The reported transaction is the purchase of a convertible note, convertible at the holder's discretion at any time into common stock at the rate of $1.25 per share. Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 19:40 UTC | AGENUS INC AGEN · Entity 5774 | GrantStock Option (Right to buy) · Derivative | 87,500 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001745285-19-000016 · primary_doc.xml · derivative · entry 1 ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2029-11-05 F1 · derivative.exercise_date: Option awarded in accordance with Agenus Inc. 2019 Equity Incentive Plan. Option vests over a three-year period, with 1/3 of Option vesting November 5, 2020, and the balance vesting in equal quarterly installments thereafter. Read SEC document |
| July 23, 2019 Filed Jul 25, 2019 23:22 UTC | AGENUS INC AGEN · Entity 5774 | GrantStock Option (Right to buy) · Derivative | 250,000 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001745285-19-000010 · primary_doc.xml · derivative · entry 1 ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-07-23 F1 · derivative.exercise_date: Stock option awarded in accordance with Agenus Inc. 2019 Equity Incentive Plan and is eligible to vest, if at all, in a single installment on June 30, 2022 based upon the Company stock price performance. Amount shown reflects the target award. The ultimate award size can range between 0% and 150% of target based on the actual average stock price achieved at the end of the performance period. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 21:35 UTC | AGENUS INC AGEN · Entity 5774 | GrantRestricted Stock Unit · Derivative | 647,682 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-017844 · doc4.xml · derivative · entry 2 ARMEN GARO H · CIK 0000935679 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 647,682 Underlying: Common Stock · 647,682 shares Expires not disclosed F2 · derivative.exercise_price: Restricted Stock Unit was granted on January 1, 2019, subject to shareholder approval of the Company's 2019 Equity Incentive Plan, which was obtained at the Company's annual shareholder meeting on June 19, 2019. Restricted Stock Unit awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan. The award vests pursuant to the performance criteria set by the Compensation Committee of the Board on December 31, 2018. F2 · price: Restricted Stock Unit was granted on January 1, 2019, subject to shareholder approval of the Company's 2019 Equity Incentive Plan, which was obtained at the Company's annual shareholder meeting on June 19, 2019. Restricted Stock Unit awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan. The award vests pursuant to the performance criteria set by the Compensation Committee of the Board on December 31, 2018. F2 · derivative.exercise_date: Restricted Stock Unit was granted on January 1, 2019, subject to shareholder approval of the Company's 2019 Equity Incentive Plan, which was obtained at the Company's annual shareholder meeting on June 19, 2019. Restricted Stock Unit awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan. The award vests pursuant to the performance criteria set by the Compensation Committee of the Board on December 31, 2018. F2 · derivative.expiration_date: Restricted Stock Unit was granted on January 1, 2019, subject to shareholder approval of the Company's 2019 Equity Incentive Plan, which was obtained at the Company's annual shareholder meeting on June 19, 2019. Restricted Stock Unit awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan. The award vests pursuant to the performance criteria set by the Compensation Committee of the Board on December 31, 2018. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 21:35 UTC | AGENUS INC AGEN · Entity 5774 | GrantStock Option, Right to buy · Derivative | 1,665,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0000899243-19-017844 · doc4.xml · derivative · entry 1 ARMEN GARO H · CIK 0000935679 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,665,000 Underlying: Common Stock · 1,665,000 shares Expires 2029-01-01 F1 · derivative.exercise_date: Option was granted on January 1, 2019, subject to shareholder approval of the Company's 2019 Equity Incentive Plan, which was obtained at the Company's annual shareholder meeting on June 19, 2019. Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan. Option vests over a three year period, with 1/3 of Option vesting on January 1, 2020, and the balance vesting in equal quarterly installments thereafter. Read SEC document |
| June 19, 2019 Filed Apr 24, 2020 21:24 UTC | AGENUS INC AGEN · Entity 5774 | GrantStock Option (Right to buy) · Derivative | 42,500 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001745285-20-000005 · primary_doc.xml · derivative · entry 3 ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2028-12-31 F4 · derivative.exercise_date: Option granted on December 31, 2018, subject to shareholder approval, which was obtained at Agenus Inc.'s annual shareholder meeting on June 19, 2019. Option awarded in accordance with Agenus Inc. 2009 Amended and Restated Equity Incentive Plan and one third of the option vested on January 1, 2020 and the balance will vest in equal quarterly installments thereafter; provided, however, that the unvested portion of such option shall vest in full upon Dr. Armen's death, disability or retirement. Read SEC document |
| September 27, 2018 Filed Dec 23, 2019 22:33 UTC | AGENUS INC AGEN · Entity 5774 | OtherCommon Stock | 225,000 | $2.16 | $486,000.00 |
DisclosureSEC source: 0001745285-19-000018 · primary_doc.xml · nonDerivative · entry 3 ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,296,433 F3 · kind: Represents deposit of Agenus Inc. common stock into the Garo Armen 2018 2 Year AG GRAT. Read SEC document |
| September 27, 2018 Filed Dec 23, 2019 22:33 UTC | AGENUS INC AGEN · Entity 5774 | OtherCommon Stock | 300,000 | $2.16 | $648,000.00 |
DisclosureSEC source: 0001745285-19-000018 · primary_doc.xml · nonDerivative · entry 2 ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,521,433 F2 · kind: Represents required distribution from the Garo Armen 2017 2 Year AG GRAT. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 15:51 UTC | AGENUS INC AGEN · Entity 5774 | GrantStock Option, right to buy · Derivative | 935,200 | $5.65 Strike: $5.65 | $5,283,880.00 |
DisclosureSEC source: 0001288123-18-000012 · primary_doc.xml · derivative · entry 1 ARMEN GARO H · CIK 0000935679 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 935,200 Underlying: Common Stock · 935,200 shares Expires 2028-03-02 F1 · derivative.exercise_date: Option was granted on March 2, 2018 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 20, 2018. Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan, and vests over three years with one-third of the award vesting on March 2, 2019 and the balance vesting in equal quarterly installments thereafter. Read SEC document |
| April 06, 2018 Filed Dec 23, 2019 22:33 UTC | AGENUS INC AGEN · Entity 5774 | OtherCommon Stock | 140,974 | $4.82 | $679,494.68 |
DisclosureSEC source: 0001745285-19-000018 · primary_doc.xml · nonDerivative · entry 1 ARMEN GARO H · CIK 0000935679 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,221,433 F1 · kind: Represents shares donated to a charitable organization. Read SEC document |
| November 30, 2017 Filed Dec 4, 2017 21:14 UTC | AGENUS INC AGEN · Entity 5774 | OtherCommon Stock | 300,000 | $3.96 | $1,188,000.00 |
DisclosureSEC source: 0001288123-17-000039 · primary_doc.xml · nonDerivative · entry 1 ARMEN GARO H · CIK 0000935679 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,290,441 F1 · kind: Represents deposit of Agenus Inc. common shares into the Garo Armen 2017 2 Year AG GRAT. Read SEC document |
| October 30, 2017 Filed Oct 30, 2017 21:05 UTC | AGENUS INC AGEN · Entity 5774 | GrantCommon Stock | 40,388 | $3.61 | $145,853.18 |
DisclosureSEC source: 0001288123-17-000037 · primary_doc.xml · nonDerivative · entry 2 ARMEN GARO H · CIK 0000935679 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,590,441 Read SEC document |
| October 30, 2017 Filed Oct 31, 2017 14:08 UTC Amendment | AGENUS INC AGEN · Entity 5774 | PurchaseCommon Stock | 40,388 | $3.61 | $145,853.18 |
DisclosureSEC source: 0001288123-17-000038 · primary_doc.xml · nonDerivative · entry 2 ARMEN GARO H · CIK 0000935679 · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,590,441 Read SEC document |
| October 27, 2017 Filed Oct 30, 2017 21:05 UTC | AGENUS INC AGEN · Entity 5774 | GrantCommon Stock | 59,612 | $3.51 | $209,261.96 |
DisclosureSEC source: 0001288123-17-000037 · primary_doc.xml · nonDerivative · entry 1 ARMEN GARO H · CIK 0000935679 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,550,053 Read SEC document |
| October 27, 2017 Filed Oct 31, 2017 14:08 UTC Amendment | AGENUS INC AGEN · Entity 5774 | PurchaseCommon Stock | 59,612 | $3.51 | $209,261.96 |
DisclosureSEC source: 0001288123-17-000038 · primary_doc.xml · nonDerivative · entry 1 ARMEN GARO H · CIK 0000935679 · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,550,053 Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 18:42 UTC | Protagenic Therapeutics, Inc.\new PTIX · Entity 8496 | GrantNon-Qualified Stock Options (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001437749-17-017237 · rdgdoc.xml · derivative · entry 1 ARMEN GARO H · CIK 0000935679 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Protagenic Therapeutics, Inc. Common Stock · 250,000 shares Expires 2027-10-16 F1 · derivative.exercise_date: Vesting in equal installments over 36 months, full vesting upon change of control Read SEC document |
| October 09, 2017 Filed Dec 14, 2017 21:46 UTC | AGENUS INC AGEN · Entity 5774 | GrantCommon Stock | 71,966 | $3.59 | $258,357.94 |
DisclosureSEC source: 0001288123-17-000045 · primary_doc.xml · nonDerivative · entry 1 ARMEN GARO H · CIK 0000935679 · CEO and Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,362,407 F1 · kind: Represents settlement of restricted shares awarded on July 1, 2015. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:06 UTC | AGENUS INC AGEN · Entity 5774 | GrantCommon Stock | 71,964 | $3.39 | $243,957.96 |
DisclosureSEC source: 0001288123-17-000021 · primary_doc.xml · nonDerivative · entry 1 ARMEN GARO H · CIK 0000935679 · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,490,441 F1 · kind: Represents settlement of vested restricted shares granted on July 1, 2015. Read SEC document |
| April 12, 2017 Filed Apr 12, 2017 21:41 UTC | AGENUS INC AGEN · Entity 5774 | PurchaseCommon Stock | 29,456 | $3.29 | $97,054.57 |
DisclosureSEC source: 0000899243-17-010077 · doc4.xml · nonDerivative · entry 2 ARMEN GARO H · CIK 0000935679 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,418,477 F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.255 to $3.33. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares purchased at each price. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 21:41 UTC | AGENUS INC AGEN · Entity 5774 | PurchaseCommon Stock | 70,544 | $3.37 | $237,465.21 |
DisclosureSEC source: 0000899243-17-010077 · doc4.xml · nonDerivative · entry 1 ARMEN GARO H · CIK 0000935679 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,389,021 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.29 to $3.43. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares purchased at each price. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 22:49 UTC | AGENUS INC agen · Entity 5774 | GrantStock Option, Right to Buy · Derivative | 853,000 | $3.77 Strike: $3.77 | $3,215,810.00 |
DisclosureSEC source: 0001288123-17-000014 · primary_doc.xml · derivative · entry 2 ARMEN GARO H · CIK 0000935679 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 853,000 Underlying: Common Stock · 853,000 shares Expires 2027-03-31 F2 · derivative.exercise_date: Option vests 100% on 5-year anniversary of the award provided Dr. Armen maintains a service relationship with the Company on such date. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 22:49 UTC | AGENUS INC agen · Entity 5774 | GrantRestricted Stock Unit · Derivative | 647,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001288123-17-000014 · primary_doc.xml · derivative · entry 1 ARMEN GARO H · CIK 0000935679 · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 647,000 Underlying: Common Stock · 647,000 shares Expires 2022-03-31 F1 · derivative.exercise_price: Award vests on March 31, 2022 if and only if the 20-day average closing price of the Company's common stock on March 31, 2022 is greater than or equal to $15 per share provided Dr. Armen maintains a service relationship with the Company at all times through such date. F1 · price: Award vests on March 31, 2022 if and only if the 20-day average closing price of the Company's common stock on March 31, 2022 is greater than or equal to $15 per share provided Dr. Armen maintains a service relationship with the Company at all times through such date. F1 · derivative.exercise_date: Award vests on March 31, 2022 if and only if the 20-day average closing price of the Company's common stock on March 31, 2022 is greater than or equal to $15 per share provided Dr. Armen maintains a service relationship with the Company at all times through such date. F1 · derivative.expiration_date: Award vests on March 31, 2022 if and only if the 20-day average closing price of the Company's common stock on March 31, 2022 is greater than or equal to $15 per share provided Dr. Armen maintains a service relationship with the Company at all times through such date. Read SEC document |
| December 22, 2016 Filed Dec 23, 2016 21:27 UTC | AGENUS INC agen · Entity 5774 | OtherCommon Stock | 152,405 | $4.06 | $618,764.30 |
DisclosureSEC source: 0001288123-16-000096 · primary_doc.xml · nonDerivative · entry 2 ARMEN GARO H · CIK 0000935679 · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,318,477 F1 · kind: Represents shares donated to a charitable organization. Read SEC document |
| December 21, 2016 Filed Dec 23, 2016 21:27 UTC | AGENUS INC agen · Entity 5774 | OtherCommon Stock | 78,001 | $4.19 | $326,824.19 |
DisclosureSEC source: 0001288123-16-000096 · primary_doc.xml · nonDerivative · entry 1 ARMEN GARO H · CIK 0000935679 · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,470,882 F1 · kind: Represents shares donated to a charitable organization. Read SEC document |
| September 16, 2016 Filed Sep 20, 2016 20:02 UTC | AGENUS INC AGEN · Entity 5774 | GrantStock Option, right to buy · Derivative | 53,037 | $0.00 Strike: $6.77 | $0.00 |
DisclosureSEC source: 0000899243-16-029397 · doc4.xml · derivative · entry 1 ARMEN GARO H · CIK 0000935679 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,037 Underlying: Common Stock · 53,037 shares Expires 2026-09-16 F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Inventive Plan, and vests in one installment on the one-year anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.